Repeated IVF Failure and the Immune System: What Is Actually Known?
Key Takeaways
Immune factors may play a role in a small subset of patients with repeated IVF failure, but they should not be treated as the default explanation after one unsuccessful cycle. Current evidence supports ruling out more common embryo, uterine, tubal, and sperm factors first, because many immune tests and immune treatments remain uncertain outside selected cases.
Key evidence: ESHRE — Recurrent implantation failure guideline ASRM — Role of immunotherapy in IVF guideline ASRM — Recurrent implantation failure committee opinion (2026)
Intralipids and IVF: what immune add-ons can and cannot do — Dr. Senai Aksoy
This video supports the immune-testing and add-on-treatment sections; it does not cover every autoimmune condition discussed in the article.
On this page
- Why the immune system is discussed
- Can IVF trigger autoimmune disease?
- More common causes still come first
- When an immune workup may be considered
- The problem with many immune tests
- What about immune treatments?
- Conclusion
Repeated IVF Failure and the Immune System: What Is Actually Known?
Patients often hear that the immune system may explain an unsuccessful embryo transfer or miscarriage after IVF. Reproductive immunology is a legitimate field, but biological plausibility is not the same as a clinically useful test. Many proposed immune tests and treatments remain unproven, and one failed transfer is not a reason for a broad immune workup (ESHRE guidance on recurrent implantation failure).
Why the Immune System Is Discussed
Short Answer:
Pregnancy depends on a controlled local immune response rather than immune silence, which is why researchers ask whether abnormal immune signaling could interfere with implantation — but that biological plausibility doesn’t mean it explains most failed cycles.
Pregnancy requires a balance between immune defense and tolerance. The embryo contains genetic material from both parents, so implantation depends on a controlled local immune response rather than simple immune silence. This has led researchers to ask whether abnormal immune signaling, inflammatory activation, or autoimmune disease could interfere with implantation in some patients.
That is biologically plausible. The harder question is how often it changes IVF decisions in practice.
Can IVF Trigger Autoimmune Disease?
Short Answer:
Current clinical evidence has not established that ovarian stimulation or embryo transfer causes a new autoimmune disease in a previously healthy woman. Care does change when an autoimmune disease is already present, and the plan depends on the condition and how active it is.
IVF changes hormone levels and can temporarily alter immune signals. That observation does not prove that treatment causes systemic autoimmune disease. The safest conclusion is that a causal link has not been established, rather than that a new illness is impossible.
The picture is different when an autoimmune disease is already present. In multiple sclerosis, the evidence on relapse after assisted reproduction is mixed; a 2023 review describes a GnRH-antagonist protocol as a reasonable preference, not as a proven way to prevent relapse (Sparaco et al., 2023). In a French prospective cohort of women with systemic lupus erythematosus, outcomes after fertility treatment did not differ significantly from spontaneous pregnancies. Most women receiving treatment had clinically inactive disease at baseline, so the finding should not be generalized to active or severe lupus (Dernoncourt et al., published online 2024; issue 2025).
If you have a known autoimmune, neurological, or rheumatological condition, it’s worth discussing the planned stimulation protocol with both your specialist — rheumatologist or neurologist — and your fertility team beforehand. Which protocol fits best — a GnRH-antagonist approach is one option — can depend on the specific disease.
Dr Aksoy’s clinical perspective
“Having an MS or lupus diagnosis doesn’t automatically mean you can’t have IVF. But there’s no such thing as a ‘standard protocol’ for you. We first look at how active the disease is, what medication you’re on, and whether pregnancy itself would be safe for you — then we plan stimulation around that.
“With an MS patient, I specifically emphasise: our goal isn’t just to retrieve eggs — it’s to do that without disturbing the balance of your disease. We review your last relapse and your medications together with your neurologist. When needed, we choose a shorter, more controlled antagonist protocol to reduce hormonal fluctuation and OHSS risk as much as possible.
“With lupus, the conversation is a little different: it matters that the disease is quiet. Active disease — especially with kidney involvement or antiphospholipid syndrome — needs a rheumatology assessment first. Rising oestrogen and pregnancy itself can matter for both disease activity and clotting risk. So we don’t start a protocol without knowing your medications, your antibody status, and your history of thrombosis.
“Where it’s needed, we may consider low-dose stimulation, an antagonist protocol, trigger methods that lower OHSS risk, and freezing all embryos to move the transfer to a safer window. But these aren’t a fixed recipe applied because of the diagnosis — they’re decisions made for that specific patient.
“Two opposite extremes bother me the most: telling a patient upfront that IVF is dangerous for her because of an autoimmune disease and ruling her out, or giving her the same protocol as everyone else as if the disease weren’t there at all. The right approach sits between the two — we’re not just stimulating your ovaries, we’re treating the whole patient. Keeping your disease under control and reaching pregnancy safely is as much a part of the treatment as the outcome itself.”
More Common Causes Still Come First
Short Answer:
Before considering an immune explanation, clinicians usually review embryo development, age-related prognosis, sperm factors, the uterine cavity, the fallopian tubes, and the transfer itself. Some findings are treatable; others help explain prognosis or guide the next attempt.
Before attributing repeated failure to immune causes, clinicians usually review:
- embryo quality and ploidy information if available,
- maternal age and ovarian reserve,
- sperm factors,
- uterine cavity findings,
- adenomyosis or endometriosis,
- hydrosalpinx,
- and transfer history.
Taken together, these domains usually provide clearer clinical next steps than an isolated immune theory. Not every factor is treatable: age and embryo ploidy, for example, mainly inform prognosis and planning.
When an Immune Workup May Be Considered
Short Answer:
Repeated implantation failure alone does not establish an immune disorder or justify a broad immune panel. Targeted testing is most defensible when the history or examination raises a specific autoimmune or clotting diagnosis that would change care.
The next step depends on the clinical question:
- A known autoimmune disease calls for disease-specific review with the relevant specialist before treatment.
- Symptoms, previous thrombosis, or other established clinical clues may justify targeted testing for a specific condition.
- Recurrent pregnancy loss has its own evidence-based evaluation; it should not be used as a shortcut to a commercial immune panel.
- Repeated implantation failure should trigger a structured review of embryo, uterine, tubal, sperm, laboratory, and transfer factors before experimental testing is discussed.
Even after repeated failure, the ASRM 2026 committee opinion finds insufficient evidence for routine antiphospholipid-antibody testing in RIF. Broad immune panels marketed after an unsuccessful transfer go beyond what current evidence supports.
The Problem With Many Immune Tests
Short Answer:
Peripheral immune markers such as natural killer cell counts or cytokine panels are hard to interpret reliably — an abnormal result doesn’t prove it caused implantation failure, and normal ranges vary across labs.
Tests involving natural killer cells, cytokine panels, and other peripheral immune markers come up often in these conversations, but they’re genuinely hard to interpret. An abnormal marker doesn’t prove it caused implantation failure, and normal ranges aren’t always standardized from lab to lab.
For that reason, professional guidance tends to be cautious. The immune hypothesis should be individualized rather than used as a universal explanation.
What About Immune Treatments?
Short Answer:
Steroids, IVIG, intralipids, and anticoagulants are different interventions with different indications. None should be offered as a routine precaution after implantation failure.
For IVF patients without another treatment indication, the ASRM immunotherapy guideline does not recommend routine corticosteroids and finds insufficient evidence for intralipids or IVIG. The 2026 RIF opinion also finds insufficient evidence for routine anticoagulation. Anticoagulation may still be prescribed for a separately confirmed condition such as antiphospholipid syndrome; that does not make steroids, IVIG, or intralipids evidence-based IVF add-ons.
The key point is that treatment should follow a defensible diagnosis rather than a vague hope that “something immune” is being covered.
Conclusion
Immune mechanisms remain an area of research, but current evidence does not support treating them as the default explanation for repeated IVF failure. Start with a structured review of embryo, uterine, tubal, sperm, laboratory, and transfer factors. Immune testing should answer a specific clinical question and should be ordered only when the result could change care.
Request a Case Review
If you’ve had more than one unsuccessful cycle, reviewing your embryo, uterine, tubal, sperm, and prior-cycle findings can help identify which questions remain open. You may request a confidential case review before deciding whether any further testing is relevant.
Related Reading
- Ways to Improve IVF Success: Evidence-Based Strategies
- IVF Success Over Time: Why More Than One Cycle Can Matter
- Frozen Embryos in IVF: When Freezing Helps and What the Tradeoffs Are
FAQ
Should immune testing be done after one failed IVF cycle?
Usually no. One failed transfer is common and does not by itself prove an immune problem. Embryo, uterine, tubal, sperm, and transfer factors usually come first.
Are natural killer cell tests definitive?
No. Peripheral immune markers can be difficult to interpret, and an abnormal result does not automatically prove that immune activity caused implantation failure.
When is immune evaluation more reasonable?
It is most useful when there is a specific clinical reason to investigate a diagnosed or suspected autoimmune or clotting disorder. Repeated implantation failure alone does not validate a broad immune panel.
Are immune treatments harmless?
No. Steroids, IVIG, intralipids, and anticoagulants can cause harm and are not interchangeable. A separate diagnosis may justify one of them, but that does not support routine immune add-ons after IVF failure.
Sources
- European Society of Human Reproduction and Embryology. Recurrent implantation failure.
- American Society for Reproductive Medicine. Role of immunotherapy in in vitro fertilization: a guideline.
- American Society for Reproductive Medicine. Recurrent implantation failure: a committee opinion (2026).
- Almohammadi A et al. Interventions for recurrent embryo implantation failure: an umbrella review.
- Sparaco M, Carbone L, Landi D, et al. Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis. CNS Drugs 2023;37(10):849-866.
- Dernoncourt A, Guettrot-Imbert G, Sentilhes L, et al. Safety of Fertility Treatments in Women With Systemic Lupus Erythematosus: Data From a Prospective Population-Based Study. BJOG 2025;132(5):614-624. Published online 2024.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.